# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
https://s27.q4cdn.com/906368049/files/News/2024/Zacks_SCR_Research_08152024_ENSC_Sorensen.pdf
Ensysce Biosciences (NASDAQ:ENSC) reported quarterly losses of $(0.22) per share which beat the analyst consensus estimate of $...
Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or the "Company"), a clinical stage pharmaceutical company d...
New Study to Confirm Overdose Protection Across Full Dosage Range of Breakthrough Therapy Opioid PF614-MPARSAN DIEGO, CA / ACCE...